Chengdu Kanghua Biological Products (300841.SZ): Recombinant hexavalent Norovirus vaccine obtains US FDA approval to enter clinical research.

Chengdu Kanghua Biological Products (300841.SZ) announced that the company has received a notification from the US Food and Drug Administration (FDA), approving the company's recombinant hexavalent rotavirus vaccine for clinical research in the United States. The recombinant hexavalent rotavirus vaccine is applicable for the prevention of rotavirus infection and acute gastroenteritis caused by rotavirus. Rotavirus is one of the main pathogens causing acute gastroenteritis outbreaks and epidemics in people of all age groups worldwide. Currently, there are no approved therapeutic drugs or preventive vaccine products for rotavirus available globally.